Want to join the conversation?
$OKE's operating costs and depreciation and amortization expense increased by 3% and 20%, respectively, for 2015, compared with 2014. This rise was due primarily to the growth of $OKS' operations related to the completed capital projects, including acquisitions, in the Natural Gas Gathering and Processing and Natural Gas Liquids segments.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.